China’s Yestar suspends trading for $200 million 6.9% notes due 2021

By William Gullotti

Buffalo, N.Y., Sept. 9 – Yestar Healthcare Holdings Co. Ltd. suspended trading of its $200 million 6.9% senior notes due Sept. 15, 2021 on the Stock Exchange of Hong Kong, according to an announcement released Thursday.

The suspension, effective immediately until maturity, comes as a result of the previously reported restructuring support agreement on July 20.

The company said it does not expect to be able to repay the principal amount of the notes or the accrued and unpaid interest due by the maturity date. This will constitute an event of default.

D.F. King Ltd. (+44 20 7920 970, +852 3953 7208 or yestar@dfkingltd.com) is the information agent.

Yestar is a Shanghai-based supplier of medical consumables for the in vitro diagnostic market and a manufacturer and distributor of medical imaging products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.